Brave New Commercialisation World: Frontiers Health 2025

Digital
Frontiers Health 2025: Off-Stage Perspectives on AI and Commercialisation

 

The commercialisation landscape in pharma is undergoing rapid transformation. At Frontiers Health 2025, we took the conversation off stage to explore what this means for global launches, pricing strategies, and patient access.

Brave New Commercialisation World
As innovative therapies reach the market, companies face unprecedented challenges: shifting global policies, evolving payer expectations, and the need to deliver value beyond the product. This extended discussion brings together insights from: Alan Crowther and Mike Ryan (EVERSANA), Andrea Forgione (MENARINI Group), and Dan Lyons (SpringWorks Therapeutics).

pharmaphorum Web Editor Nicole Raleigh leads a discussion that covers:

  • How policy changes like Most Favoured Nations pricing are reshaping pricing and access
  • Why aligning innovation with adoption is critical for success
  • The importance of creating holistic value propositions that resonate with payers, clinicians, and patients
  • Strategies for navigating complexity while accelerating time-to-market

Watch the full interview to gain practical insights into the forces redefining commercialisation and market access in a rapidly changing global environment.